Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

1.7K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
1.7K
Antigen Presenting Cells01:22

Antigen Presenting Cells

3.5K
The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
3.5K
Types of Receptors: Cell Surface Receptors01:28

Types of Receptors: Cell Surface Receptors

28.0K
Cell-surface receptors, also known as transmembrane receptors, are cell surface, membrane-anchored (integral) proteins that bind to external ligand molecules. This type of receptor spans the plasma membrane and performs signal transduction, converting an extracellular signal into an intracellular signal. Ligands that interact with cell-surface receptors do not have to enter the cell that they affect. Cell-surface receptors are also called cell-specific proteins or markers because they are...
28.0K
Internal Receptors01:31

Internal Receptors

74.8K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.8K
Gene Therapy00:59

Gene Therapy

27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

111.6K
Overview
111.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PBMs and Rising Costs.

Missouri medicine·2024
Same author

Expanded Access Versus Right-to-Try.

Hospital pharmacy·2020
Same author

New Medications in the Treatment of Acute Migraine.

Hospital pharmacy·2019
Same author

Impact of Dispensing Services in an Independent Community Pharmacy.

Pharmacy (Basel, Switzerland)·2019
Same author

FDA Guidance and New Drug Approvals.

Hospital pharmacy·2018
Same author

New Medications in the Treatment of Peanut Allergy.

Hospital pharmacy·2018

Related Experiment Video

Updated: Feb 16, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.5K

Chimeric Antigen Receptor T-Cell Therapy for Lymphomas.

Benjamin Jolley1, Scot Walker2

  • 1St. Louis College of Pharmacy, MO, USA.

Hospital Pharmacy
|December 26, 2017
PubMed
Summary

Chimeric antigen receptor T-cell (CAR T-cell) therapies offer a potent new strategy for treating non-Hodgkin lymphoma (NHL), inducing remission in many patients. However, severe cytokine release syndrome is a significant side effect requiring careful management.

Keywords:
formulary management/P&Tinvestigational drugsoncology

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.6K

Related Experiment Videos

Last Updated: Feb 16, 2026

Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.6K

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Non-Hodgkin lymphoma (NHL) affects 2.1% of the US population, with a 5-year survival rate of 71% post-treatment.
  • Current NHL treatments have limitations, including incomplete cure rates and significant adverse effects.
  • Novel therapeutic strategies are crucial for improving outcomes in NHL patients.

Purpose of the Study:

  • To review the development of chimeric antigen receptor T-cell (CAR T-cell) therapies for lymphoma treatment.
  • To highlight the potential and challenges associated with CAR T-cell therapy in oncology.

Main Methods:

  • Review of current literature on CAR T-cell therapy development for lymphoma.
  • Analysis of efficacy and safety data from clinical studies of CAR T-cell therapies.

Main Results:

  • CAR T-cell therapies demonstrate high potency, achieving complete remission in 50% to 80% of patients.
  • A common adverse effect is cytokine release syndrome (CRS), with approximately one-third of patients experiencing a severe form.
  • Ongoing research focuses on optimizing CAR T-cell therapy to maximize benefits and minimize toxicity.

Conclusions:

  • CAR T-cell therapy represents a promising advancement in the treatment of non-Hodgkin lymphoma.
  • Managing severe cytokine release syndrome is critical for the safe and effective application of CAR T-cell therapies.
  • Further development is needed to refine CAR T-cell strategies and expand their clinical utility.